FDA Warns Hims Over Ads About Compounded Weight-Loss Drugs
1. Hims & Hers received FDA warning letters about misleading product claims. 2. The letters targeted over 100 companies for selling misbranded drugs online. 3. Hims's compounded semaglutide products were specifically mentioned in the warnings. 4. Stock price fell over 6% after the announcement but is up 11.7% this month. 5. The warnings come amid recent regulatory changes aimed at drug advertising.